Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Antigenics, Inc. Q2 2009 Earnings Call Transcript
- Question-and-Answer Session Operator Operator Instructions. Your first question comes from the line of Ren Benjamin - Rodman & Renshaw. Ren Benjamin - Rodman & Renshaw Starting off with Oncophage, thanks for the review of the clinical data. I thought that the subset analysis actually got split into...
- Earnings calls 2009-07-30
Additional Resources
- Ligand Confirms That ECOG Has Initiated a Multi-Center Phase II study of ONTAK for Non-Hodgkin's Lymphoma
- SAN DIEGO--BW HealthWire--May 10, 1999-- Ligand Pharmaceuticals Incorporated (Nasdaq:LGND) confirmed today that the Eastern Cooperative Oncology Group ECOG of the National Cancer Institute has initiated a Phase II study of ONTAKTM (denileukin diftitox, DAB389 IL2) in patients with non-Hodgkin's lymphoma NHL. Ligand is currently marketing ONTAK for patients with...
- Research articles 1999-05-10
- Genentech Q2 2007 Earnings Call Transcript
- Question-and-Answer SessionOperator Your first question comes from Gene Mack - HSBC Securities. Gene Mack - HSBC Securities Thanks for taking my question. When might we get to see the final overall survival data from the ECOG 2100 trial? Sue Hellmann The trial as...
- Earnings calls 2007-07-11
- REVLIMID® Data for Newly Diagnosed Multiple Myeloma Reported at a Satellite Symposium During the 13th European Hematology Association Congress
- COPENHAGEN, Denmark -- Data from the ECOG E4A03 and SWOG 0232 studies were reported at a Satellite Symposium and showed that newly diagnosed multiple myeloma patients who are eligible for a transplant, obtain better outcomes when treated with REVLIMID lenalidomide plus dexamethasone. The data were presented by Dr A. Stewart,...
- Research articles 2008-06-16
- Celgene Corp. Q1 2008 Earnings Call Transcript
- Question-and-Answer SessionThank you. [Operator Instructions] And we will pause for a moment to assemble the roster. We'll go first to Yaron Werber with Citi. Yaron Werber - Citigroup Yes, hi, good morning. I have two questions for you. One, can you give us the sense on the Rev growth...
- Earnings calls 2008-05-08
- Celgene Q2 2007 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions We’ll go first to Ian Somaiya with Thomas Weisel Partners. Ian Somaiya – Thomas Weisel Partners Thanks for taking my question. I had a couple of questions for Bob and one for Sol. The two questions for Bob, first...
- Earnings calls 2007-07-26
- Genentech, Inc. Q2 2006 Earnings Conference Call Transcript (DNA)
- Question-and-Answer SessionOperator Operator Instructions Your first question comes from Joel Sendek with Lazard Capital Markets. Joel Sendek - Lazard Frères & Co. Thanks a lot. Can you give us some sense of what percentage of Avastin sales in the second quarter was...
- Earnings calls 2006-07-11
- EquityAlert.com Announces Investment Opinion
- Business Editors NOTE TO EDITORS: The following is an investment opinion issued by EquityAlert.com VANCOUVER, BRITISH COLUMBIA--BUSINESS WIRE--May 30, 2000 EquityAlert.com (OTCBB:EINC) Progenics Loses 69.75% On News Of ECOG Withdrawl EquityAlert.com (www.equityalert.com), one of the largest online trader-exclusive communities, provides free real time news...
- Research articles 2000-05-30
- << Previous
- page 1 of 1
- Next >>
